A group of over 100 institutional investors have written to Dutch medical technology company Philips demanding compensation of €800 million for “significant losses to shareholders” over the sleep ...

Philips will sell its emergency care business to investment firm Bridgefield Capital for an undisclosed amount. The deal is ...

The deal includes a licensing agreement that allows the sold business to use the Philips brand for up to 15 years.

The Class I recall, the FDA’s severest classification, is a correction and does not require removing devices from where they are used or sold. Philips started the recall on Nov. 20, 2024 ...

ResMed Inc . (NYSE:RMD; ASX:RMD), a leading player in the sleep and respiratory care market, has demonstrated strong operational performance in recent quarters. However, the company faces potential ...

Due to its significant market share and high gross margins in a structurally growing industry, ResMed has posted an average return on invested capital, or ROIC, of 20% over the last decade. We ...

The FDA is elevating a recall from Philips related to one of its wearable outpatient heart monitors, used to help detect cases of hidden, transient arrhythmias that may only last minutes at a time.

Philips is recalling the software associated with its mobile cardiac outpatient telemetry devices after 109 patient injuries and two patient deaths, a Jan. 13 FDA recall notice said. The software ...

Although RMD has re-rated from its share price low of around $21.50 in October 2023, it has only just surpassed its all-time ...

Fisher & Paykel is well-positioned to benefit from long-term growth prospects in hospital and home respiratory care. Increasing adoption of nasal high flow, or NHF, therapy in the hospital division is ...